Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations

Cancers
Susumu IiizumiTetsuro Sasada

Abstract

Neoantigens derived from tumor-specific genetic mutations might be suitable targets for cancer immunotherapy because of their high immunogenicity. In the current study, we evaluated the immunogenicity of 10 driver mutations that are frequently expressed in various cancers using peripheral blood mononuclear cells from healthy donors (n = 25). Of the 10 synthetic peptides (27-mer) derived from these mutations, the six peptides from KRAS-G12D, KRAS-G12R, KRAS-G13D, NRAS-Q61R, PIK3CA-H1047R, and C-Kit-D816V induced T cell responses, suggesting that frequent driver mutations are not always less immunogenic. In particular, immune responses to PIK3CA-H1047R, C-Kit-D816V, KRAS-G13D, and NRAS-Q61R were observed in more than 10% of the donors. All six peptides induced human leukocyte antigen (HLA) class II-restricted CD4⁺ T cell responses; notably, PIK3CA-H1047R contained at least two different CD4⁺ T cell epitopes restricted to different HLA class II alleles. In addition, PIK3CA-H1047R and C-Kit-D816V induced antigen-specific CD8⁺ T cells as well, indicating that they might contain both HLA class I- and class II-restricted epitopes. Since the identified neoantigens might be shared by patients with various types of cancers and are not ea...Continue Reading

References

Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin A CheeverLynn M Matrisian
Dec 24, 2011·Nature·Ira MellmanGlenn Dranoff
May 17, 2012·Cancer Research·Ian A PriorCarla Mattos
Aug 16, 2013·Current Pharmaceutical Design·Karmen StankovMomir Mikov
May 20, 2014·Immunity·Alexander Mildner, Steffen Jung
Jul 22, 2014·Nature·Theresa SchumacherMichael Platten
Dec 11, 2014·Annual Review of Immunology·Jamie RossjohnJames McCluskey
Feb 18, 2015·Journal of Clinical Pathology·K LaiC S Lee
Mar 3, 2015·Current Opinion in Immunology·Thomas BlankensteinHans Schreiber
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Apr 23, 2015·Nature·Sebastian KreiterUgur Sahin
May 8, 2016·Biochemical and Biophysical Research Communications·Hiroshi HamanaAtsushi Muraguchi
May 21, 2016·Science·Erlend StrønenTon N Schumacher
Dec 14, 2016·The New England Journal of Medicine·Eric TranSteven A Rosenberg
Jul 6, 2017·Nature·Patrick A OttCatherine J Wu
Nov 7, 2017·Cell·Rachel MartyHannah Carter
Dec 6, 2017·The Journal of Experimental Medicine·Zinal S ChhedaHideho Okada
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee
Jan 24, 2018·The Journal of Clinical Investigation·Joshua R VeatchStanley R Riddell
Mar 24, 2018·Science·Ugur Sahin, Özlem Türeci
Jul 31, 2018·Nature Reviews. Immunology·Jannie BorstWolfgang Kastenmüller
Sep 25, 2018·Cell·Rachel Marty PykeHannah Carter
Dec 14, 2018·Oncoimmunology·Lucillia BezuLorenzo Galluzzi
Dec 18, 2018·Nature Biotechnology·Brendan Bulik-SullivanRoman Yelensky

❮ Previous
Next ❯

Citations

Oct 16, 2019·Nature Biotechnology·Binbin ChenAsh A Alizadeh
Mar 17, 2020·Expert Review of Vaccines·Ying ZhangWen-Hao Luo
Jul 28, 2019·Cancers·Vasso Apostolopoulos
Jul 16, 2020·Vaccines·Nurul Ainaa Adilah Rus BakarurrainiNadiah Abu
Feb 12, 2021·Frontiers in Immunology·Heather F JonesDavid A Scheinberg
Jun 16, 2021·Genome Medicine·Christof C SmithAlex Rubinsteyn
Jun 26, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Noam LevinSteven A Rosenberg
Oct 16, 2021·The Journal of Clinical Investigation·Aviyah PeriYardena Samuels

❮ Previous
Next ❯

Methods Mentioned

BETA
density gradient centrifugation
ELISA
Assay

Software Mentioned

FACSDiva

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.